跳至主要内容
临床试验/NCT04675801
NCT04675801Unknown不适用

Safety and Efficacy of Bridging Antithrombotic Therapy During Elective Non-cardiac Surgery for Coronary Artery Disease Patients Treated With Oral Antiplatelet Agents

Beijing Anzhen Hospital1 个研究点 分布在 1 个国家目标入组 950 人开始时间: 2021年3月2日最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
950
试验地点
1
主要终点
Major adverse cardiovascular events

研究概览

简要总结

Patients with coronary artery disease, especially after PCI, require long-term oral antiplatelet therapy. However, this patient population may inevitably require non-cardiac surgery for a variety of conditions. In order to avoid the occurrence of bleeding events, oral antiplatelet agents are usually discontinued before non-cardiac surgery in patients with coronary artery disease, which may increase the incidence of ischemic events. Therefore, it is important to provide patients with the optimal perioperative antithrombotic treatment to balance the risk of bleeding and ischemia.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Aged 18 years or over
  • Established coronary artery disease being treated with oral antiplatelet therapy
  • Non-cardiac surgery is planned and bridging antithrombotic therapy is considered necessary
  • Agree to participate in the study and provide written informed consent

排除标准

  • According to the consensus of Chinese experts on antiplatelet therapy in 2013, the surgical bleeding risk is low or extremely low
  • Requiring emergency non-cardiac surgery within 24 hours after admission
  • Currently being bleeding
  • Moderate or severe ischemic stroke or spontaneous intracranial hemorrhage in the past 6 months or traumatic intracranial hemorrhage in the past 1 year
  • Intracranial diseases or hemorrhagic diathesis
  • Contraindications for LMWH or GP IIb/IIIa receptor antagonists

结局指标

主要结局

Major adverse cardiovascular events

时间窗: Perioperative period

A composite of all-cause death, non-fatal myocardial infarction, or non-fatal stroke

次要结局

  • TIMI major or minor bleeding(Perioperative period)
  • Net adverse clinical events(30 days after surgery)

研究者

发起方
Beijing Anzhen Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Yujie Zhou

PhD, MD

Beijing Anzhen Hospital

研究点 (1)

Loading locations...

相似试验